MARKET

TRAW

TRAW

Traws Pharma
NASDAQ
1.715
+0.035
+2.08%
Opening 15:32 05/13 EDT
OPEN
1.610
PREV CLOSE
1.680
HIGH
1.770
LOW
1.580
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
3.265
52 WEEK LOW
0.9700
MARKET CAP
25.98M
P/E (TTM)
2.092
1D
5D
1M
3M
1Y
5Y
1D
Moderna’s stock has rallied on hantavirus research that is ‘early-stage’ in nature
MarketWatch · 2d ago
Weekly Report: what happened at TRAW last week (0504-0508)?
Weekly Report · 2d ago
Chuck Schumer Blasts Trump, Elon Musk For Firing CDC And Port Health Workers As Hantavirus Scare Grips The World
Benzinga · 2d ago
Traws Pharma files to sell 35.9M shares of common stock for holders
TipRanks · 4d ago
There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call’ to develop some.
MarketWatch · 5d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 5d ago
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
Benzinga · 5d ago
Traws Climbs 20% On Hantavirus Drug Development Push
NASDAQ · 5d ago
More
About TRAW
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Webull offers Traws Pharma Inc stock information, including NASDAQ: TRAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRAW stock methods without spending real money on the virtual paper trading platform.